TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05753293

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: Buteyko breathing technique developed to control hyperventilation and anxiety which leads to shortness of breath. It uses series of exercises to teach patients to breathe less deeply and less rapidly /Bhastrika Bellow Breathing is diaphragmatic breathing - deep breathing involving the diaphragm rather than the accessory muscles. Regulated pranayama exercises require inhalation, maintaining isometric contraction of respiratory muscles and forceful expiration. These techniques will strengthen respiratory muscles
Study: NCT06313723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal education management delivered via podcast
Description: Pregnant women assigned to the intervention group (52) will be listened to podcasts on a Samsung Galaxy J7 Prime brand phone while undergoing a 20-minute NST procedure
Study: NCT05153954

Intervention type: OTHER
Intervention: Quantitative Indocyanine Green Fluorescence Angiography
Description: Quantitative analyse of ICG around the proximal/oral part of the anastomosis pre-formation of the primary anasomosis
Study: NCT06268613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB27
Description: Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EU sourced Keytruda
Description: Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: US sourced Keytruda
Description: Will be administered intravenously at a fixed dose of 200 mg every 3 weeks, maximum 18 cycles over about 51 weeks
Study: NCT05988203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT166a
Description: Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT166a
Description: Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT166a
Description: Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT166a
Description: Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT166a
Description: Multivalent ribonucleic acid (RNA)-based vaccine for active immunization against monkeypox administered as intramuscular injection.
Study: NCT06645067

Intervention type: BEHAVIORAL
Intervention: Measuring energy balance
Description: The exercise intervention will consist of a personalized and supervised program lasting 12 weeks with two sessions per week, held on Tuesdays and Thursdays at the Sports and Medicine Center SPORMED in Rennes, France.~Each session will combine endurance and resistance training, commencing with a 6-minute cardiovascular warm-up on ergometers (cycling ergometer or treadmill). This will be followed by 20 minutes at moderate intensity (60-70% of Heart Rate Reserve (HRR)), concluding with a 2-minute recovery period at light intensity. We will measure the resting ED at the start of the programme and the ED during moderate aerobic exercise in the 5th week of APA.
Study: NCT05636436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
Study: NCT06643715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PANDA PLUS
Description: Using the PANDA PLUS model to assist in image interpretation, radiologists are provided with the model's output classification-non-PDAC, PDAC, or normal-alongside the initial CT image assessment. The radiologists then integrate the information from both the PANDA PLUS output and the original image interpretation to formulate the final report.
Study: NCT06643910

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single drug group A
Description: 9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined treatment group B
Description: 9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled
Study: NCT06643182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Back Support
Description: When the sandbag is to be left by the researcher together with the nurse caring for the patient, the patient will be placed in the left lateral position for a short time, a gel-filled orthopedic non-sweating viscose pillow will be placed in the patient's lumbar region and the patient will be placed in a supine position with the head supported.
Study: NCT06645262

Intervention type: OTHER
Intervention: Cryotherapy
Description: cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.

Intervention type: OTHER
Intervention: Cryotherapy
Description: cryotherapy, therapeutic exercises, the use of braces, and the Bowen technique.
Study: NCT06644898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Level walking training
Description: For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Downhill walking training
Description: For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uphill walking training
Description: For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
Study: NCT06645405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI algorithm
Description: Artificial intelligence algorithms in the automated reconstruction of intracranial large vessel occlusion (LVO)
Study: NCT05548920

Intervention type: OTHER
Intervention: Ultrasound guided Superior Vena Cava Collapsibility Index
Description: Preoperative Ultrasound guided Superior Vena Cava Collapsibility Index will be measured

Intervention type: OTHER
Intervention: Inferior Vena Cava Collapsibility Index
Description: Preoperative Inferior Vena Cava Collapsibility Index will be measured.
Study: NCT05636436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
Study: NCT05415215

Intervention type: DRUG
Group type: OTHER
Intervention: Investigator's Choice of Chemotherapy
Description: Option 1: Docetaxel and carboplatin once every 3 weeks for 6 cycles; Option 2: Doxorubicin plus cyclophosphamide once every 3 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles); Option 3: Dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks for 4 cycles, followed by a taxane (docetaxel once every 3 weeks for 4 cycles or paclitaxel once every week for 12 cycles).
Study: NCT05636436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High Dose Recombinant Herpes Zoster Vaccine (CHO cells)
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adjuvant
Description: 0.5 mL per dose, containing low dose MA105 adjuvant.
Study: NCT04608682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
Study: NCT05636436

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose adjuvant
Description: 0.5 mL per dose, containing low dose MA105 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: 0.5 mL per dose, containing high dose MA105 adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose adjuvant
Description: 0.5 mL per dose, containing high dose MA105 adjuvant.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive control
Description: 0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL per dose, containing 4.5 mg sodium chloride.
Study: NCT06299605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
Study: NCT05493722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS and OS stimulation order 1
Description: PS, OS, OS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS and OS stimulation order 2
Description: OS, PS, OS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PS and OS stimulation order 3
Description: OS, OS, PS
Study: NCT04600180

Intervention type: PROCEDURE
Intervention: sigmoidoscopies and and venous blood sampling
Description: Sigmoidoscopies will be performed at baseline and during immunotherapy. During these procedures biopsies will be taken from the sigmoid and rectum. At the same timepoints, venous blood samples will be taken.
Study: NCT06312358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Building Capacity for Infant Achievements in Child Care
Description: All teacher participants will be assigned to the professional development intervention consisting of an interactive workshop and weekly coaching sessions.
Study: NCT05660187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis Clinical Care Delivery via telehealth
Description: Intervention includes clinical care delivered via telehealth
Study: NCT05929807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TransCon CNP
Description: TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
Study: NCT06402435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lvonescimab (AK112)
Description: 8Gy\*3 SBRT (continuous irradiation) to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT (continuous irradiation) irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK112 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) for 4 cycles. The immunotherapy drug used was Lvonescimab (AK112).
Study: NCT06313684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Initial Assessment
Description: Initial Assessment includes all those necessary to prescribe exercise training, as well as dietary and adherence promotion interventions.~* Functional capacity with 6MWT~* Assessment of skeletal muscle strength, flexibility, and balance.~* Assessment of function~* Assessment of dietary habits~* Assessment of self-efficacy and barriers to CR adherence.~* Screening for depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous evaluation
Description: Evaluations during the course of the program will be carried out to inform the progression through the CR stages, the intensity of training and education needs.
Study: NCT05660187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multiple Sclerosis Clinical Care Delivery via standard in clinic visits
Description: Intervention includes clinical care delivered via standard in clinic visits
Study: NCT05415215

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery
Description: After completing their neoadjuvant therapy, participants will undergo surgical resection for early or locally advanced HER2+ breast cancer (if eligible for surgery). Participants may undergo breast-conserving surgery or mastectomy according to routine clinical practice. The surgery cannot be performed ≤2 weeks from the last systemic neoadjuvant therapy and must be performed ≤6 weeks after the last systemic neoadjuvant therapy.
Study: NCT06313684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval Exercise
Description: High-intensity interval training prescribed by physical therapist:~* According to an adapted Wisloff protocol.~* Borg scale to monitor intensity.~* Training 3 times per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial support
Description: Based on social-cognitive theory, with self-efficacy as a focus:~* Face-to-face sessions in the first stage of the program: Education, self-monitoring and motivational interview.~* Face-to-face session in the second stage of the program: promoting behavior changes by self-control and self-monitoring~* Regular communication with patients will be supported by the use of mobile devices during the third and fourth stages of program.
Study: NCT05504746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 capsule
Description: Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHEN26 capsule
Description: Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose.
Study: NCT05707936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Flush 20 ml
Description: Normal Saline Flush 20 ml
Study: NCT06313684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet management
Description: A dietary plan supported by a nutritionist will be made together with the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise
Description: Resistance exercises:~* With TheraBand.~* Intensity according to the perceived exertion scale~* Twice a week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous exercise
Description: Moderate-intensity continuous exercise prescribed by physical therapist :~* The intensity will be moderate, as tolerated~* Borg scale to monitor intensity.~* Frequency of training of 1 to 3 times per week, until completed 20 sessions in 10-12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Assessment
Description: Includes all those necessary to plan exercise training, as usual:~* Functional capacity with 6MWT.~* Assessment of skeletal muscle strength.
Study: NCT06528457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISLA101
Description: ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISLA101
Description: ISLA101 is an oral gelatin capsule containing 100 mg of fenretinide (N-\[4-Hydroxyphenyl\]retinamide, mw 391.56) dissolved in corn oil and polysorbate 80. ISLA101 capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
Study: NCT05415215

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiotherapy
Description: After surgery, radiotherapy is to be given as clinically indicated and as per local practice or institutional standards. The selected radiotherapy regimen should be initiated within 4 weeks after surgery.
Study: NCT05707936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline Flush 10 ml
Description: Normal Saline Flush 10 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Flush (1000 USP, 10ml)
Description: Heparin Flush (1000 USP, 10ml)
Study: NCT05721157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-enabled Chest X-ray-based Screening Tool
Description: Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-Chest X-ray result was positive or negative.The system will send a message to corresponding physicians if positive finding.
Study: NCT05504746

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHEN26 placebo
Description: Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days.
Study: NCT06225544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumasiran
Description: Subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride (placebo)
Description: Placebo, subcutaneous injection, given as three monthly loading doses followed by one further maintenance dose.
Study: NCT06528457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
Description: The DENV-1-LVHC investigational challenge material consists of the dengue-1 virus strain 45AZ5 as a powder, lyophilized for reconstitution. The product is reconstituted with 0.7 mL of water for injection (WFI) and diluted to a concentration of 6.5 x 103 PFU/mL.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally as one dose of 300 mg/m2 each 12 hours (q12 +/-1 h).
Study: NCT05036772

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: The experimental arm will have the possibility to use a distracting virutel environment for the duration of hysterosalpingography.
Study: NCT06270719

Intervention type: GENETIC
Intervention: Delandistrogene Moxeparvovec
Description: No study medication will be provided by the sponsor during this study.

Intervention type: DRUG
Intervention: Standard of Care
Description: No study medication will be provided by the sponsor during this study.